Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Agendia
Agendia's MammaPrint breast cancer prognosis test validated by international consortium
October 13th, 2006
In a publication in the Journal of the National Cancer Institute, made available online on September 6, 2006, the international consortium TRANSBIG reports the validation and the clinical utility of Agendia's Mammaprint breast cancer prognosis test (TRANSBIG: European Union 6th framework program Translational Research Breast International Group). In this study, 307 breast cancer patients from five different European centers were compared for their risk for metastatic disease either by Agendia's MammaPrint test or by conventional clinico-pathological risk assessment as determined by the Adjuvant! software. The study found that the MammaPrint...
Source: Medicine & Law Weekly (2006-10-13)
|
